Literature DB >> 27814581

Mitochondrial dysfunction and prostate cancer racial disparities among American men.

Ajay K Chaudhary1, Jordan O'Malley1, Sandeep Kumar1, Joseph R Inigo1, Rahul Kumar1, Neelu Yadav1, Dhyan Chandra2.   

Abstract

The gap between prostate cancer disparities among American men is narrowing, which is mostly due to increased screening of African American (AA) men. However, the biological reasons for prostate cancer disparities among American men still remain undefined. Mitochondrion, an organelle within cells, regulates both cell survival and cell death mechanisms. These cellular signaling pathways require various proteins localized to mitochondria, which are encoded by both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Interestingly, prostate tissues from AA men harbor reduced mtDNA content compared to Caucasian American (CA) men. Therefore, changes in mitochondrial genes may have detrimental consequences in terms of cellular signaling regulated by mitochondria in AA men. This review describes the plausible underlying mechanism of mtDNA depletion and its impact in driving resistance to therapy leading to faster progression and poor prognosis in African American men with prostate cancer. Since defective cellular signaling is critical for prostate cancer cell survival, restoring mitochondrial function may provide strategies to alleviate prostate cancer disparities among American men.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27814581     DOI: 10.2741/s479

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  6 in total

Review 1.  Racial disparities, cancer and response to oxidative stress.

Authors:  Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew
Journal:  Adv Cancer Res       Date:  2019-04-23       Impact factor: 6.242

2.  Decreased Mitochondrial Dynamics Is Associated with Insulin Resistance, Metabolic Rate, and Fitness in African Americans.

Authors:  John J Dubé; Michael L Collyer; Sara Trant; Frederico G S Toledo; Bret H Goodpaster; Erin E Kershaw; James P DeLany
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 3.  Targeting mitochondrial metabolism for metastatic cancer therapy.

Authors:  Antonino Passaniti; Myoung Sook Kim; Brian M Polster; Paul Shapiro
Journal:  Mol Carcinog       Date:  2022-06-20       Impact factor: 5.139

Review 4.  Contribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations.

Authors:  Dayan Sun; Yang Wei; Hong-Xiang Zheng; Li Jin; Jiucun Wang
Journal:  Front Mol Biosci       Date:  2019-11-15

Review 5.  Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine - comprehensive effects of phytochemicals in primary, secondary and tertiary care.

Authors:  Alena Mazurakova; Marek Samec; Lenka Koklesova; Kamil Biringer; Erik Kudela; Raghad Khalid Al-Ishaq; Martin Pec; Frank A Giordano; Dietrich Büsselberg; Peter Kubatka; Olga Golubnitschaja
Journal:  EPMA J       Date:  2022-07-08       Impact factor: 8.836

6.  Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk.

Authors:  Jialin Xiao; Lauren Howard; Junxiang Wan; Emily Wiggins; Adriana Vidal; Pinchas Cohen; Stephen J Freedland
Journal:  Oncotarget       Date:  2017-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.